Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory diffuse large B-cell lymphoma: Results of a global randomized phase III trial (STARGLO)

Data from the phase 3 STARGLO trial—presented during the European Hematology Association (EHA) 2024 Congress—in patients with relapsed/refractory DLBCL demonstrated that glofitamab plus gemcitabine and oxaliplatin produced an overall survival benefit of 25.5 months, compared with 12.9 months among patients who received rituximab plus gemcitabine and oxaliplatin (HR 0.62, 95% CI: 0.43–0.88). Median progression-free survival was 13.8 vs 3.6 months (HR 0.40, 95% CI: 0.28–0.57), and the complete response rate was 58.5 vs 25.3%, respectively.